A Phase II Study of TARCEVA (erlotinib) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 09 Sep 2015 Interim results (n= 59) presented at the 16th World Conference on Lung Cancer
- 01 Jun 2015 Interim results (n=46) published in the International Journal of Radiation Oncology, Biology, Physics